Charles River Laboratories’ Shanghai facility has received a Certificate of Good Laboratory Practice (GLP) compliance from the Organization for Economic Cooperation and Development (OECD). The certificate acknowledges the site is operating in compliance with OECD Principles of GLP for both toxicology and lab services.

The one-week inspection, conducted by the Belgian national GLP compliance monitoring authority, included an audit of three completed and two on-going studies. It evaluated key operations areas including: vivarium rooms, pharmacy, analytical chemistry, bioanalytical chemistry, clinical pathology, and histopathology.

“Our China facility was established on the premise that we would provide our clients with the same high standards of research, safety, animal welfare and good lab practices that distinguish Charles River,” said James C. Foster, chairman, president and chief executive officer of Charles River. “As the first preclinical CRO to receive a Certificate of Compliance from an OECD member country, Charles River is positioned to help our clients develop IND-enabling programs at our Shanghai facility. This certification marks a significant milestone in our commitment to strategically partner with our clients globally to accelerate their drug development programs.”